Stocktoria
aTYR PHARMA INC ATYR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-05-07
aTYR PHARMA INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 |
| R&D expense | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M |
| EPS (diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M |
| Cash & equivalents | $10.7M | $11.1M | $22.5M | $10.0M | $2.3M |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M |
| Shareholders' equity | $67.5M | $70.0M | $90.7M | $71.5M | $109.3M |
Source: SEC EDGAR filings · CIK 0001339970 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.